Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$5.5 million.

  • ARS Pharmaceuticals' Capital Expenditures fell 404357.14% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641000.0, marking a year-over-year increase of 27705.88%. This contributed to the annual value of $563000.0 for FY2024, which is 22171.43% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Capital Expenditures of -$5.5 million as of Q3 2025, which was down 404357.14% from $5.8 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Capital Expenditures peaked at $5.8 million during Q2 2025, and registered a low of -$5.5 million during Q3 2025.
  • In the last 5 years, ARS Pharmaceuticals' Capital Expenditures had a median value of $83000.0 in 2024 and averaged $70052.6.
  • Examining YoY changes over the last 5 years, ARS Pharmaceuticals' Capital Expenditures showed a top increase of 1508157.89% in 2025 and a maximum decrease of 404357.14% in 2025.
  • ARS Pharmaceuticals' Capital Expenditures (Quarter) stood at -$767000.0 in 2021, then soared by 116.43% to $126000.0 in 2022, then crashed by 172.22% to -$91000.0 in 2023, then skyrocketed by 431.87% to $302000.0 in 2024, then tumbled by 1928.15% to -$5.5 million in 2025.
  • Its Capital Expenditures stands at -$5.5 million for Q3 2025, versus $5.8 million for Q2 2025 and $91000.0 for Q1 2025.